Payment overview · 2025
General Payments
$70.75
4 reported records · 2 companies
Healthcare provider profile · identity verified
L.J. Patrick Bell, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HELENA, AR · NPI 1871589309
Verified facts
What the public records show
CMS Open Payments records show L.J. Patrick Bell, D.O. received $70.75 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 54.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.76 | 54.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.99 | 45.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $70.75 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.76 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.99 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 445 | 142 |
| Gabapentin | Gabapentin | 392 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 368 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 364 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 338 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 336 | 89 |
| Furosemide | Furosemide | 314 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 311 | 64 |
| Glipizide | Glipizide | 309 | 70 |
| Lisinopril | Lisinopril | 290 | 68 |
| Simvastatin | Simvastatin | 282 | 71 |
| Promethazine Hcl | Promethazine Hcl | 269 | 139 |
| Tizanidine Hcl | Tizanidine Hcl | 255 | 106 |
| Potassium Chloride | Potassium Chloride | 251 | 63 |
| Tramadol Hcl | Tramadol Hcl | 249 | 74 |
| Montelukast Sodium | Montelukast Sodium | 239 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 225 | 56 |
| Meloxicam | Meloxicam | 209 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 206 | 44 |
| Omeprazole | Omeprazole | 203 | 60 |
| Azithromycin | Azithromycin | 199 | 148 |
| Temazepam | Temazepam | 197 | 46 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 181 | 44 |
| Lorazepam | Lorazepam | 170 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 165 | 54 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 159 | 41 |
| Metformin Hcl | Metformin Hcl | 158 | 44 |
| Allopurinol | Allopurinol | 154 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 70 |
| Losartan Potassium | Losartan Potassium | 152 | 37 |
| Prednisone | Prednisone | 139 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 132 | 26 |
| Eliquis | Apixaban | 129 | 27 |
| Clonidine Hcl | Clonidine Hcl | 125 | 28 |
| Nifedipine Er | Nifedipine | 118 | 26 |
| Carvedilol | Carvedilol | 117 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 40 |
| Jardiance | Empagliflozin | 112 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 105 | 66 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 103 | 85 |
| Cefadroxil | Cefadroxil | 103 | 75 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 103 | 57 |
| Sucralfate | Sucralfate | 97 | 40 |
| Alprazolam | Alprazolam | 88 | 13 |
| Famotidine | Famotidine | 86 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 80 | 24 |
| Mounjaro | Tirzepatide | 80 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 69 | 17 |
| Meclizine Hcl | Meclizine Hcl | 68 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 16 |
| Diazepam | Diazepam | 62 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 19 |
| Terazosin Hcl | Terazosin Hcl | 62 | 14 |
| Gemfibrozil | Gemfibrozil | 60 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 59 | 24 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Ibuprofen | Ibuprofen | 55 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 22 |
| Mupirocin | Mupirocin | 52 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 12 |
| Methocarbamol | Methocarbamol | 49 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 12 |
| Lactulose | Lactulose | 47 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 11 |
| Acyclovir | Acyclovir | 44 | 14 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 44 | suppressed |
| Glipizide Er | Glipizide | 43 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 23 |
| Baclofen | Baclofen | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 18 |
| Atenolol | Atenolol | 37 | 14 |
| Digoxin | Digoxin | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | 13 |
| Linzess | Linaclotide | 35 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 20 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 23 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 23 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 18 |
| Megestrol Acetate | Megestrol Acetate | 27 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Indomethacin | Indomethacin | 26 | 12 |
| Ozempic | Semaglutide | 26 | 13 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Nystatin | Nystatin | 22 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Piroxicam | Piroxicam | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Phenytoin | Phenytoin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70.75 · 4 records | AstraZeneca Pharmaceuticals LP | FARXIGA, Ozempic, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error